GlassScriptPhysician profile
Mark A Stefaniuk
NPI 1013932409
$4,959.52
in general payments reported to CMS, 2019-2025
30 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $349 · 2023: $899 · 2024: $1,226 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,885.00 | 2021-2025 | Eterna, Proclaim |
| Corcept Therapeutics | $407.46 | 2024-2025 | Korlym |
| Boston Scientific Corporation | $376.74 | 2021-2023 | |
| Pfizer INC. | $313.90 | 2022-2025 | |
| Lilly USA, LLC | $215.73 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Lundbeck LLC | $207.45 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $198.06 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Foundation Fusion Solutions, LLC | $196.55 | 2023 | |
| Spinal Simplicity, LLC | $180.85 | 2025 | Ha Minuteman G3-R |
| Axsome Therapeutics, INC. | $180.56 | 2025 | Symbravo |
| Eisai INC. | $126.16 | 2025 | |
| Exact Sciences Corporation | $88.02 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $70.75 | 2024-2025 | Airsupra, Breztri |
| Cleerly, INC. | $66.12 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Amgen INC. | $57.78 | 2024-2025 | Krystexxa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.81 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $39.91 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $32.59 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Madrigal Pharmaceuticals | $30.04 | 2025 | Rezdiffra |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| C2n Diagnostics, LLC | $22.30 | 2025 | Precivityad2 |
| Biogen, INC. | $21.23 | 2025 | Skyclarys |
| Rgh Enterprises LLC | $20.86 | 2025 | |
| Baxter Healthcare | $19.90 | 2024 | Biopharma Sol - Contract Manuf |
| Antares Pharma, INC. | $18.85 | 2025 | Xyosted |
| Lucid Diagnostics INC. | $16.51 | 2025 | |
| Philips North America LLC | $15.13 | 2024 | (Ck7) Extended Holter |
| Medicure Pharma INC. | $15.04 | 2024 | Zypitamag |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stefaniuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.